Virus-like-particles or virosomes

Virus-like particles (VLPs) and virosomes, have been developed depending on the nature of the viral pathogen to be targeted and the type of immune response (humoral vs cellular) to be elicited. Particulate structures allow the insertion or fusion of foreign antigenic sequences, resulting in chimeric particles delivering foreign antigens on their surface. Similarly, they are used as carriers for foreign antigens, including non-protein antigens, via chemical conjugation.



What is virosome technology?

Virosome technology is a tool for developing novel, predominantly synthetic vaccines against infectious and chronic diseases. A virosome is a virus-like particle that acts as a vaccine carrier and adjuvant (immunity enhancing) system. Vaccines based on virosome technology combine high efficacy with high purity, which means they are effective and safe to use even in infants and individuals with a weakened immune system.

What is virosome technology?

Virosome technology is a tool for developing novel, predominantly synthetic vaccines against infectious and chronic diseases. A virosome is a virus-like particle that acts as a vaccine carrier and adjuvant (immunity enhancing) system. Vaccines based on virosome technology combine high efficacy with high purity, which means they are effective and safe to use even in infants and individuals with a weakened immune system.
Key Strengths

• Virosome technology provides a versatile system for delivering virus antigens or DNA/RNA encoding specific immune-stimulatory proteins.

• Virosome technology enables target-specific delivery of antigens and amplification of the immune response.

• Virosomes stimulate both arms of the immune system, eliciting both antibody and cellular immune responses to maximize protection against the targeted disease.

• Virosomes are completely biodegradable and can exert an immune response via different routes of administration.